Cargando…

Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer

Stereotactic body radiation therapy (SBRT) can positively influence an antitumor immune response by inducing necrotic cell death. SBRT also been shown to eliminate tumors outside the radiation therapy field through an immune-mediated process known as the abscopal effect. Recent advances in immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustafson, Michael P., Bornschlegl, Svetlana, Park, Sean S., Gastineau, Dennis A., Roberts, Lewis R., Dietz, Allan B., Hallemeier, Christopher L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707422/
https://www.ncbi.nlm.nih.gov/pubmed/29204520
http://dx.doi.org/10.1016/j.adro.2017.08.003
_version_ 1783282421349744640
author Gustafson, Michael P.
Bornschlegl, Svetlana
Park, Sean S.
Gastineau, Dennis A.
Roberts, Lewis R.
Dietz, Allan B.
Hallemeier, Christopher L.
author_facet Gustafson, Michael P.
Bornschlegl, Svetlana
Park, Sean S.
Gastineau, Dennis A.
Roberts, Lewis R.
Dietz, Allan B.
Hallemeier, Christopher L.
author_sort Gustafson, Michael P.
collection PubMed
description Stereotactic body radiation therapy (SBRT) can positively influence an antitumor immune response by inducing necrotic cell death. SBRT also been shown to eliminate tumors outside the radiation therapy field through an immune-mediated process known as the abscopal effect. Recent advances in immunotherapy may provide new therapeutic approaches for patients with liver cancer. Therefore, understanding the immune status of patients with cancer will likely guide how immunotherapy might be used in combination with SBRT. We hypothesized that we would observe changes in circulating blood immune cell populations of patients who received SBRT for liver tumors. Therefore, we assessed 110 immunophenotypes in the peripheral blood of 10 patients with liver cancer or metastases to the liver pretreatment and 2 posttreatment time points. Patients with liver cancer and metastatic patients both exhibited several immunophenotypic abnormalities at baseline compared with a group of healthy volunteer controls. In longitudinal studies, SBRT caused a specific reduction in CD3(+) T cell counts and immature CD56(br)CD16(−) NK cell counts. The immune profiling and potential identification of circulating biomarkers shown here could lead to the design of combinatorial approaches with SBRT and immunotherapy to optimize the timing of treatment and direct the most effective immunotherapy with SBRT.
format Online
Article
Text
id pubmed-5707422
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57074222017-12-04 Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer Gustafson, Michael P. Bornschlegl, Svetlana Park, Sean S. Gastineau, Dennis A. Roberts, Lewis R. Dietz, Allan B. Hallemeier, Christopher L. Adv Radiat Oncol Biology Stereotactic body radiation therapy (SBRT) can positively influence an antitumor immune response by inducing necrotic cell death. SBRT also been shown to eliminate tumors outside the radiation therapy field through an immune-mediated process known as the abscopal effect. Recent advances in immunotherapy may provide new therapeutic approaches for patients with liver cancer. Therefore, understanding the immune status of patients with cancer will likely guide how immunotherapy might be used in combination with SBRT. We hypothesized that we would observe changes in circulating blood immune cell populations of patients who received SBRT for liver tumors. Therefore, we assessed 110 immunophenotypes in the peripheral blood of 10 patients with liver cancer or metastases to the liver pretreatment and 2 posttreatment time points. Patients with liver cancer and metastatic patients both exhibited several immunophenotypic abnormalities at baseline compared with a group of healthy volunteer controls. In longitudinal studies, SBRT caused a specific reduction in CD3(+) T cell counts and immature CD56(br)CD16(−) NK cell counts. The immune profiling and potential identification of circulating biomarkers shown here could lead to the design of combinatorial approaches with SBRT and immunotherapy to optimize the timing of treatment and direct the most effective immunotherapy with SBRT. Elsevier 2017-08-18 /pmc/articles/PMC5707422/ /pubmed/29204520 http://dx.doi.org/10.1016/j.adro.2017.08.003 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Biology
Gustafson, Michael P.
Bornschlegl, Svetlana
Park, Sean S.
Gastineau, Dennis A.
Roberts, Lewis R.
Dietz, Allan B.
Hallemeier, Christopher L.
Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title_full Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title_fullStr Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title_full_unstemmed Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title_short Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
title_sort comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
topic Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707422/
https://www.ncbi.nlm.nih.gov/pubmed/29204520
http://dx.doi.org/10.1016/j.adro.2017.08.003
work_keys_str_mv AT gustafsonmichaelp comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT bornschleglsvetlana comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT parkseans comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT gastineaudennisa comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT robertslewisr comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT dietzallanb comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer
AT hallemeierchristopherl comprehensiveassessmentofcirculatingimmunecellpopulationsinresponsetostereotacticbodyradiationtherapyinpatientswithlivercancer